Enliven Therapeutics, Inc. · NASDAQ:ELVN

Fairmount Funds Management LLC reported a 6.30% stake in Enliven Therapeutics, Inc. (Schedule 13G/A)

Event Jun 30, 2025 · Filed Aug 14, 2025

Fairmount Funds Management LLC reported a 6.30% stake in Enliven Therapeutics, Inc., 3,711,444 shares, as a passive investor on Jun 30, 2025. Filed Aug 14, 2025 (Schedule 13G/A).

Stake
6.30%
Shares
3,711,444
Intent
Passive
What changed
Stake changed
Filed together
4 holders

The filing in full

HolderStakeShares
Fairmount Funds Management LLC6.30%3,711,444
Fairmount Healthcare Fund II L.P.6.30%3,711,444
Peter Harwin6.30%3,711,444
Tomas Kiselak6.30%3,711,444

Source

View original at SEC

Related